Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes

Jun 9, 2017 - (Newswire)

- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced positive top-line results from its Phase 3 inTandem3 study of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of patients with type 1 diabetes on any background insulin therapy. The study met its primary endpoint, demonstrating the superiority of sotagliflozin 400 mg compared to placebo in the proportion of patients with A1C

Original Source: https://www.newswire.com/news/lexicon-pharmaceuticals-reports-positive-top-line-results-in-phase-3-intandem3

What Next?

Related Articles

Leave a Reply

Submit Comment